Fate Therapeutics, Inc. FATE
2.04 USD +0.03 (+1.49%)
At closeNov 3, 2026, 4:08 PM EST
2.07 +0.03 +1.47%
After hours · Nov 3, 4:08 PM ET
2.01 Day range 2.12
0.95 52-week range 3.23
- YTD
- +108.16%
- 1 year
- +61.90%
Analyst view
Consensus: buy
Buy
Price target (mean) 6.31 +209.2% upside
Now 2.04
- Target (low)
- 3.00
- Target (mean)
- 6.31
- Target (high)
- 10.00
Ratings (0m) 18 6 buy · 12 hold · 0 sell
- Strong buy2
- Buy4
- Hold12
- Sell0
- Strong sell0
Recommendation trend
- This month 18
- 1 month ago 18
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.43055 | -0.49 – -0.35 | -0.45 | +4.3% | 1.57M | -6.5% | 14 |
| Next quarter | -0.455 | -0.50 – -0.38 | -0.47 | +3.2% | 1.20M | -37.8% | 8 |
| Current year | -1.59 | -1.77 – -1.18 | -1.64 | +3.2% | 13.65M | -78.5% | 14 |
| Next year | -1.63 | -2.07 – -0.80 | -1.59 | -2.9% | 4.19M | -69.3% | 14 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Needham | Reiterated | — | Hold |
| Nov 13, 2024 | Needham | Reiterated | — | Hold |
| Aug 22, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Aug 14, 2024 | Needham | Reiterated | — | Hold |
| Jun 17, 2024 | Piper Sandler | Upgrade | Neutral | Overweight |
| May 16, 2024 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| May 10, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| May 10, 2024 | BMO Capital | Maintained | Market Perform | Market Perform |
| May 10, 2024 | Wedbush | Maintained | Neutral | Neutral |
| May 10, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| May 6, 2024 | Wedbush | Reiterated | Neutral | Neutral |
| Apr 23, 2024 | Wedbush | Reiterated | Neutral | Neutral |
| Apr 11, 2024 | Needham | Reiterated | — | Hold |
| Mar 28, 2024 | B of A Securities | Maintained | Underperform | Underperform |
| Mar 19, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Feb 27, 2024 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Feb 27, 2024 | BMO Capital | Maintained | Market Perform | Market Perform |
| Feb 27, 2024 | Barclays | Maintained | Overweight | Overweight |
| Feb 27, 2024 | Wedbush | Maintained | Neutral | Neutral |
| Feb 27, 2024 | Oppenheimer | Reiterated | Perform | Perform |
| Nov 20, 2023 | Mizuho | Maintained | Buy | Buy |
| Nov 13, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Nov 9, 2023 | BMO Capital | Maintained | Market Perform | Market Perform |
| Nov 9, 2023 | Wedbush | Maintained | Neutral | Neutral |
| Nov 9, 2023 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Sep 7, 2023 | Cantor Fitzgerald | Reiterated | Neutral | Neutral |
| Aug 16, 2023 | Truist Securities | Reiterated | Hold | Hold |
| Aug 10, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 10, 2023 | Barclays | Maintained | Overweight | Overweight |
| Aug 9, 2023 | BMO Capital | Maintained | Market Perform | Market Perform |